HealesMovies | EHA 2022 - 1.3. Oligonucleotide senotherapies for the diseases of ageing (Lorna Harries) @HealesMovies | Uploaded December 2022 | Updated October 2024, 24 minutes ago.
Lorna Harries is Professor of Molecular Genetics at the University of Exeter College of Medicine and Health. She gained her PhD in Genetics from University College London in November 1994 and now leads the RNA-mediated disease mechanisms group at the University of Exeter College of Medicine and Health. Her group has interests in alternative messenger RNA processing, non-coding RNA and epigenetic gene regulation in the context of ageing and chronic disease.
Professor Lorna Harries holds a personal chair in molecular genetics at the University of Exeter Medical School, where she leads the RNA-mediated disease mechanisms group, and a position as Co-Founder, director and Chief Scientific Officer for SENISCA (www.senisca.com), a senotherapeutics spin out company built on research form the Harries team. Lorna has interests in omics approaches to the study of human ageing and age-related disease processes in man, and her work ranges from ‘big data’ analyses to detailed individual molecular analysis of particular genes. Her team were the first to report dysregulation of alternative splicing as a new, and druggable, hallmark of ageing.
medicine.exeter.ac.uk/people/profile/index.php?web_id=Lorna_Harries
Lorna Harries is Professor of Molecular Genetics at the University of Exeter College of Medicine and Health. She gained her PhD in Genetics from University College London in November 1994 and now leads the RNA-mediated disease mechanisms group at the University of Exeter College of Medicine and Health. Her group has interests in alternative messenger RNA processing, non-coding RNA and epigenetic gene regulation in the context of ageing and chronic disease.
Professor Lorna Harries holds a personal chair in molecular genetics at the University of Exeter Medical School, where she leads the RNA-mediated disease mechanisms group, and a position as Co-Founder, director and Chief Scientific Officer for SENISCA (www.senisca.com), a senotherapeutics spin out company built on research form the Harries team. Lorna has interests in omics approaches to the study of human ageing and age-related disease processes in man, and her work ranges from ‘big data’ analyses to detailed individual molecular analysis of particular genes. Her team were the first to report dysregulation of alternative splicing as a new, and druggable, hallmark of ageing.
medicine.exeter.ac.uk/people/profile/index.php?web_id=Lorna_Harries
